Ryo Sadachi

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).

Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto et al. · Journal of Clinical Oncology · 2022 · 107 citations

Medicine, Cancer Biology, Oncology +17

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System

Chigusa Morizane, Nozomu Machida, Yoshitaka Honma et al. · JAMA Oncology · 2022 · 93 citations · Full text

Medicine, Oncology, Pharmacology +16

Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial

Akihiro Ohba, Chigusa Morizane, Makoto Ueno et al. · Future Oncology · 2022 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17

Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial

Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto et al. · Journal of Clinical Oncology · 2024 · 50 citations · Full text

Medicine, Oncology, Pharmacology +16

Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study

Takafumi Koyama, Toshio Shimizu, Yuki Kojima et al. · Cancer Discovery · 2023 · 43 citations

Medicine, Oncology, Pharmacology +13